

Multisample Inference

Outline

1. One-Way ANOVA--- Fixed Effects
 - ① One-Way ANOVA
 - ② Post-hoc Test After One-Way ANOVA
2. Two-Way ANOVA
3. The Kruskal-Wallis Test
4. One-Way ANOVA--- Random Effects
5. Meta Analysis
6. Mixed Model

One-Way ANOVA

Qualitative Factor

Fixed Effects

Example:

Pulmonary disease

- A topic of public-health interest is whether *passive smoking* (exposure among nonsmokers to cigarette smoke in the atmosphere) has a measurable effect on pulmonary (肺部) health.
 - Endpoint: Forced Mid-expiratory flow (FEF) in L/s
 - 6 groups:
 - nonsmokers (NS),
 - passive smokers (PS),
 - noninhaling smokers (NI),
 - light smokers (LS),
 - moderate smokers (MS),
 - heavy smokers (HS)

FEF data for smoking and nonsmoking males

Group name	Mean FEF	SD FEF	n
NS	3.78	0.79	200
PS	3.30	0.77	200
NI	3.32	0.86	50
LS	3.23	0.78	200
MS	2.73	0.81	200
HS	2.59	0.82	200

One-Way ANOVA--- Fixed Effects

- Can be viewed in two different ways:
 - Extension of “two-sample” t-test to more than two groups.
 - Extension of simple linear regression to case where X is qualitative. => multiple regression

One-way ANOVA model

- k groups and n_i observations in the i th group
- y_{ij} : the j th observation in the i th group

$$y_{ij} = \mu + \alpha_i + e_{ij}, e_{ij} \sim N(0, \sigma^2).$$

- Constraint needed for “identifiability”
 - $\sum_{i=1}^k \alpha_i = 0$ (we use this approach here)
 - $\alpha_k = 0$

Interpretation

$$y_{ij} = \mu + \alpha_i + e_{ij}, e_{ij} \sim N(0, \sigma^2).$$

- μ : the underlying mean of all groups taken together.
- α_i : the difference between the mean of the i th group and the overall mean.
- e_{ij} : random error about the mean $\mu + \alpha_i$ for an individual observation from the i th group.

Multiple linear regression

- Recall: One-way ANOVA

$$y_{ij} = \mu + \alpha_i + e_{ij}, e_{ij} \sim N(0, \sigma^2).$$

- This is equivalent to:

$$y = \alpha + \sum_{j=1}^{k-1} \beta_j x_j + e$$

- where $x_j = I(\text{subject is in group } (j + 1))$ is **dummy** variable. And group 1 is referred to as the **reference group**.
- β_j : the difference between the average value of y for subjects in group $(j+1)$ vs. the average value of y for subjects in the reference group.

. One-way ANOVA(fixed effect) Multiple linear regression

Overall comparison

- | | |
|---|--|
| • $H_0: \alpha_1 = \cdots = \alpha_k = 0$ | • $H_0: \beta_1 = \cdots = \beta_k = 0$ |
| • H_1 : at least one of the $\alpha_j \neq 0$ | • H_1 : at least one of the $\beta_j \neq 0$ |
| • F test | • F test |
| – Between SS <u> </u> | – Regression SS |
| – Within SS <u> </u> | – Residual SS |

The F statistic and p-values are the same

Testing in One-way ANOVA

1. Simplest question: is there any group (main) effect?

$$H_0: \alpha_1 = \cdots = \alpha_k = 0?$$

2. Other questions: is the effect the same in groups 1 and 2?

$$H_0: \alpha_1 = \alpha_2?$$

Partitioning the variance

- Let $\bar{y}_i = \frac{\sum_{j=1}^{n_i} y_{ij}}{n_i}$, and $\bar{\bar{y}} = \frac{\sum_{i=1}^k \sum_{j=1}^{n_i} y_{ij}}{n}$, $n = \sum_{i=1}^k n_i$.
- $$y_{ij} - \bar{\bar{y}} = (y_{ij} - \bar{y}_i) + (\bar{y}_i - \bar{\bar{y}})$$


$$\sum_{i=1}^k \sum_{j=1}^{n_i} (y_{ij} - \bar{\bar{y}})^2 = \sum_{i=1}^k \sum_{j=1}^{n_i} (y_{ij} - \bar{y}_i)^2 + \sum_{i=1}^k \sum_{j=1}^{n_i} (\bar{y}_i - \bar{\bar{y}})^2$$

Total SS = Within SS + Between SS
- In shorthand:

$$\begin{array}{lll} \text{SSTO} & = & \text{SSW} \quad + \quad \text{SSB} \\ \sim \sigma^2 \chi^2(n-1) & & \sim \sigma^2 \chi^2(n-k) \quad \sim \sigma^2 \chi^2(k-1, \lambda) \end{array}$$
- $$MSB = \hat{\sigma}_B^2 = \frac{SSB}{k-1}, \quad MSW = \hat{\sigma}_W^2 = \frac{SSW}{n-k}$$

One-way ANOVA: the picture

- Comparison of between-group and within-group variability



(a)

Back to the hypothesis testing

- Is there any group (main) effect? (**overall comparison**)

$$H_0: \alpha_1 = \cdots = \alpha_r = 0$$

$$H_1: \text{at least one } \alpha_i \neq 0$$

- The null hypothesis specifies a global relationship between the means.
- Our test statistic is

$$F = \frac{MSB}{MSW} = \frac{\hat{\sigma}_B^2}{\hat{\sigma}_W^2} = \frac{\text{variance between the groups}}{\text{variance within the groups}}$$

The F-statistic

- Under H_0

$$F \sim F_{k-1, n-k}$$

- Thus
 - Reject H_0 if $F > F_{\alpha, k-1, n-k}$
 - Fail to reject H_0 if $F \leq F_{\alpha, k-1, n-k}$
- $F_{\alpha, k-1, n-k}$ is the value on the $F_{k-1, n-k}$ distribution that, used as a cutoff, gives an area in the upper tail = α
- And the exact p-value is given by the area to the right of F under an the $F_{k-1, n-k}$ distribution = $\Pr(F_{k-1, n-k} > F)$

A one-way ANOVA table

The results from the ANOVA are typically displayed in an ANOVA table, as in the following table:

Source of variation	SS	df	MS	F statistic	p-value
Between	$\sum_{i=1}^k \sum_{j=1}^{n_i} (\bar{y}_i - \bar{\bar{y}})^2 = \text{SSB}$	$k - 1$	$\frac{\text{SSB}}{k - 1} = \text{MSB}$	$\frac{\text{MSB}}{\text{MSW}}$	$\Pr(F_{k-1, n-k} > F)$
Within	$\sum_{i=1}^k \sum_{j=1}^{n_i} (y_{ij} - \bar{y}_i)^2 = \text{SSW}$	$n - k$	$\frac{\text{SSW}}{n - k} = \text{MSW}$		
Total	$\text{SST} = \text{SSB} + \text{SSW}$	$n - 1$			

Example: ANOVA for Pulmonary disease

Outcomes: Mid-expiratory flow (FEF) in L/s

Group name	Mean FEF	SD FEF	n
NS	3.78	0.79	200
PS	3.30	0.77	200
NI	3.32	0.86	50
LS	3.23	0.78	200
MS	2.73	0.81	200
HS	2.59	0.82	200

Pulmonary disease

ANOVA result

- We obtain the following result from **Pulmonary disease** example

	SS	df	MS	F statistic	P-value
Between	184.38	5	36.875	58.0	<0.001
Within	663.87	1044	0.636		
Total	848.25				

- Conclusions
 - Since $F = 58.0 > F_{0.001,5,1044} = 4.14$, we reject H_0
 - There is a significant difference in the mean FEF among the groups(P-value<0.001).

Testing in One-way ANOVA

1. Simplest question: is there any group (main) effect?

$$H_0: \alpha_1 = \cdots = \alpha_k = 0?$$

2. Other questions: is the effect the same in groups 1 and 2?

$$H_0: \alpha_1 = \alpha_2?$$

Which groups are different?

- We might proceed to make **individual comparisons**.
E.g., is the effect the same in groups 1 and 2?

$$H_0: \alpha_1 = \alpha_2?$$

- Conduct two-sample t-tests to test for a difference in means for each pair of groups (assuming equal variance):

$$t = \frac{\bar{y}_1 - \bar{y}_2}{s \sqrt{\frac{1}{n_1} + \frac{1}{n_2}}}$$

- Recall: $s = \hat{\sigma}_W^2 = MSW$ is the 'pooled' sample estimate of the common variance

The t-statistic

- Under H_0

$$t \sim t_{n-k}$$

- Thus

- Reject H_0 if $t > t_{\alpha/2, n-k}$ or $t < t_{1-\alpha/2, n-k}$
- Fail to reject H_0 if $t_{1-\alpha/2, n-k} \leq t \leq t_{\alpha/2, n-k}$

- And the exact p-value is given by

$$p = \begin{cases} 2 \times \Pr(t_{n-k} < t), & \text{if } t < 0 \\ 2 \times \Pr(t_{n-k} > t), & \text{if } t \geq 0 \end{cases}$$

- This test is often referred to as the *least significant difference* (LSD) method

Multiple Comparisons

- Performing individual comparisons require multiple hypothesis tests
- If $\alpha = 0.05$ for each comparison, there is a 5% chance that each comparison will falsely be called significant
- Overall, the probability of Type I error is elevated above 5%
- For n independent tests, the probability of making a Type I error at least once is $1 - (1 - 0.05)^n$
 - Example: For $n = 10$ tests, the probability of at least one Type I error is 0.40 !
- Question: How can we address this multiple comparisons issue?

Multiple Testing

- Differentially expressed genes detection

	Case				Control			
Gene 1	X_{11}	X_{12}	...	X_{1n_1}	Y_{11}	Y_{12}	...	Y_{1n_1}
• 2	X_{11}	X_{11}	...	X_{11}	Y_{11}	Y_{11}	...	Y_{11}
⋮	⋮	⋮	⋮	⋮	⋮	⋮	⋮	⋮
n	⋮	⋮	⋮	⋮	⋮	⋮	⋮	⋮

- Different genes may have different gene expression levels
- For each gene, two-sample t-test ...
 - ⇒ Multiple testing problem

FWER

- Type I error, $\alpha = 0.05$ in the ordinary hypothesis testing

- Multiple hypothesis testing:


$$H_{i0}: \mu_{i1} = \mu_{i2}, i = 1, 2, \dots, n$$

- Family wise type I error rate (FWER)

$$\text{FWER} = P(\cup_{i=1}^n A_i) = 1 - \prod_{i=1}^n (1 - \alpha_i)$$

A_i : type I error occurs in the i -th hypothesis testing

Bonferroni Adjustment

- A possible correction for multiple comparisons
- Test each hypothesis at level $\alpha^* = \alpha / \binom{k}{2}$  FWER
- **Basic idea:** ensures overall Type I error rate does not exceed $\alpha = 0.05$
 - For example, for our **Pulmonary disease**, $k = 6$, given $\alpha = .05$, thus $\alpha^* = .05 / \binom{6}{2} = 0.0033$
- However, this adjustment may be too conservative

False-Discovery Rate

- Control of FWER may result great loss in detection power

⇒ An alternative approach based on the *false-discovery rate* (FDR)

	Null hypothesis is true (H_0)	Alternative hypothesis is true (H_A)	Total
Test is declared significant	V	S	R
Test is declared non-significant	U	T	$m - R$
Total	m_0	$m - m_0$	m

- Basic idea: attempts to control the **proportion of false positive results among reported statistically significant results**.

FDR vs. FWER

	Null hypothesis is true (H_0)	Alternative hypothesis is true (H_A)	Total
Test is declared significant	V	S	R
Test is declared non-significant	U	T	$m - R$
Total	m_0	$m - m_0$	m

- $Q = \begin{cases} V/R, & R > 0 \\ 0, & R = 0 \end{cases}$
- $\text{FDR} = E(Q) = E(V/R \mid R > 0)P(R > 0)$
- $\text{FWER} = P(V \geq 1)$
- If $m = m_0$, $\text{FDR} = E(1 \mid R > 0)P(R > 0) = P(R > 0) = P(V > 0) = \text{FWER}$;
- If $m > m_0$, $0 < V/R \leq 1 \Rightarrow V/R \leq I(V > 0) \Rightarrow \text{FDR} \leq \text{FWER}$
- Controlling FDR may gain power comparing to controlling

FDR Testing Procedure (BH, 1995)

- Procedure:
 1. For a given α , find the largest k such that $p_k \leq \frac{k}{m} \alpha$,
 2. Reject the null hypothesis for all H_i for $i = 1, 2, \dots, k$.

which ensures that $E(Q) \leq \frac{m_0}{m} \alpha \leq \alpha$

- R function: `p.adjust`

BH Procedure in textbook

- ① Suppose we have conducted k separate tests with p -values = p_1, \dots, p_k .
- ② For convenience we will renumber the tests so that $p_1 \leq p_2 \leq \dots \leq p_k$.
- ③ Define $q_i = kp_i/i$, $i = 1, \dots, k$, where i = rank of the p -values among the k tests.
- ④ Let FDR_i = false-discovery rate for the i th test be defined by $\min(q_i, \dots, q_k)$.
- ⑤ Find the largest i such that $\text{FDR}_i < \text{FDR}_0$ = critical level for the FDR (usually .05).
- ⑥ Reject H_0 for the hypotheses $1, \dots, i$, and accept H_0 for the remaining hypotheses.

FDR related concepts

- $Fdr = \frac{E(V)}{E(R)}$, $pFDR = E(\frac{V}{R} | R > 0)$
- Finding the truly alternative hypotheses is regarded as identifying a small component in a mixture, i.e.,

$$p \sim \pi_0 f_0 + (1 - \pi_0) f_1,$$

where $p|H_0 \sim f_0$ and $p|H_1 \sim f_1$, and $\pi_0 \cong 1$

- Empirical Bayes method
(ref: Large-scale inference, Bradley Efron, 2010)
- $FDR(x) = \frac{\pi_0 F_0(x)}{F(x)}$ = prob. of being null / prob. of being rejected
- $local\ fdr(x) = \frac{\pi_0 f_0(x)}{f(x)} = P(H_0|x)$
prob. of being null given $x/1$

Demonstrating example: I

- A subsample of 520 cases of cardiovascular disease (CVD) and 1100 controls was obtained among men in a prospective cohort study.
- Baseline blood samples were analyzed for 50 candidate single nucleotide polymorphisms (SNPs).
- The association of each SNP with CVD was assessed using contingency-table methods.
- A chi-square test for trend was run for each SNP. This yielded 50 separate p -values. => next slide

Demonstrating example: II

Use of the FDR approach to analyzing the CVD data

	SNP	Naïve p -value	Bonferroni p -value	q_i	FDR _{i}
1	gene30	<.0001	.0035	.0035	.0035
2	gene20	.011	.54	.28	.16
3	gene48	.017	.86	.28	.16
4	gene50	.017	.87	.22	.16
5	gene4	.018	.92	.18	.16
6	gene40	.019	.94	.16	.16
7	gene7	.026	1.00	.18	.18
8	gene14	.034	1.00	.21	.21
9	gene26	.042	1.00	.23	.23
10	gene47	.048	1.00	.24	.24

Case study: LEAD


- we analyzed the **difference in mean** finger-wrist tapping score (MAXFWT) by three lead-exposure groups according to the variable LEAD_TYPE:
 - If LEAD_GRP = 1, then the child had normal blood-lead levels ($<40 \mu\text{g}/100 \text{ mL}$) in both 1972 and 1973 (control group).
 - If LEAD_GRP = 2, then the child had elevated blood-lead levels ($\geq 40 \mu\text{g}/100 \text{ mL}$) in 1973 (the currently exposed group).
 - If LEAD_GRP = 3, then the child had elevated blood-lead levels in 1972 and normal blood-lead levels in 1973 (the previously exposed group).

First look at the data

Descriptive statistics by group

Group (<i>g</i>)	N	N(no missing)	Mean	Std Dev
1	77	63	55.09524	10.93487
2	22	17	47.58824	7.08042
3	21	15	49.40000	10.19664

Box-plot by group



```
boxplot(maxfwt~Lead_type)
```

R codes: I

LEAD

```
> summary(fit <- aov(maxfwt~g))
              Df Sum Sq Mean Sq F value    Pr(>F)
g              2  966.8   483.40   4.5985 0.01249 *
Residuals    92 9671.1  105.12
---
Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
25 observations deleted due to missingness
> pairwise.t.test(maxfwt,Lead_type,p.adjust.method =
"none") # t test
```

Pairwise comparisons using t tests with pooled SD

data: maxfwt and Lead_type

	1	2
2	0.0087	-
3	0.0563	0.6191

R codes: II

LEAD

```
> pairwise.t.test(maxfwt,Lead_type,p.adjust.method = "bonferroni")  
# Bonferroni correction
```

Pairwise comparisons using t tests with pooled SD

data: maxfwt and Lead_type

	1	2
2	0.026	-
3	0.169	1.000

P value adjustment method: bonferroni

```
> pairwise.t.test(maxfwt,Lead_type,p.adjust.method = "BH")  
# FDR: False Discovery rate control
```

Pairwise comparisons using t tests with pooled SD

data: maxfwt and Lead_type

	1	2
2	0.026	-
3	0.084	0.619

P value adjustment method: BH


Two-Way ANOVA

Two-Way ANOVA

- We have learned the fixed-effects one-way ANOVA, in which groups were defined by only one variable, e.g., cigarette smoking.
- In some instances, the groups being considered can be classified by two different variables and thus can be arranged in the form of an $R \times C$ contingency table.
- We would like to be able to look at the effects of each variable after controlling for the effects of the other variable.
- => the two-way ANOVA.

Example:

Kidney



- Recovery time depends on weight gain between treatments and duration of treatment.
- Two levels of duration, three levels of weight gain.

Definition

- **Main effect**
 - effect of one treatment variable considered in isolation (ignoring other variables in the study)
- **Interaction effect**
 - the effect of one variable depends on the level of the other variable.
 - For example:
 - SV males have mean SBP levels that are 10 mm Hg lower than those of normal males, whereas SV females have mean SBP levels identical to those of normal females.
 - => an interaction effect between sex and dietary group

Two-way ANOVA model

- General model

$$y_{ijk} = \mu + \alpha_i + \beta_j + \gamma_{ij} + e_{ijk}$$

- where $e_{ij} \sim N(0, \sigma^2)$.
- Constraint needed for “identifiability”
 - $\sum_{i=1}^r \alpha_i = \sum_{j=1}^c \beta_j = 0$
 - $\sum_{i=1}^r \gamma_{ij} = 0$, for all j
 - $\sum_{j=1}^c \gamma_{ij} = 0$, for all i
- Using dummy variables, this is still a multiple regression problem.

Interpretation

$$y_{ijk} = \mu + \alpha_i + \beta_j + \gamma_{ij} + e_{ijk}$$

- μ : the underlying mean of all groups taken together.
- α_i : the effect of row group
- β_j : the effect of column group
- γ_{ij} : the interaction effect between row group and column group.
- e_{ijk} : random error about the mean $\mu + \alpha_i + \beta_j + \gamma_{ij}$ for an individual observation from the i th group.

Testing in Two-way ANOVA

1. Are there main effects for the grouping variables?

$$H_0: \alpha_1 = \cdots = \alpha_r = 0$$

$$H_0: \beta_1 = \cdots = \beta_c = 0$$

2. Are there interaction effects?

$$H_0: \gamma_{ij} = 0, 1 \leq i \leq r, 1 \leq j \leq c.$$

Two-way ANOVA table

Source of variation	$SS(n_{ij} = n)$	df
Row (A)	$nc \sum_{i=1}^r (\bar{y}_{i..} - \bar{y}_{...})^2 = SSA$	$r-1$
Column(B)	$nr \sum_{j=1}^c (\bar{y}_{.j.} - \bar{y}_{...})^2 = SSB$	$c-1$
Interaction(AB)	$n \sum_{i=1}^r \sum_{j=1}^c (\bar{y}_{ij.} - \bar{y}_{i..} + \bar{y}_{.j.} - \bar{y}_{...})^2 = SSAB$	$(r-1)(c-1)$
Error	$\sum_{i=1}^r \sum_{j=1}^c (y_{ijk} - \bar{y}_{ij.})^2 = SSE$	$(n-1)rc$
Total	$SST = SSA + SSB + SSAB + SSE$	$nc-1$

F-tests for two-way ANOVA

- $MS = SS/df$

- F-test

$$F_A = \frac{MSA}{SSE} \sim F(r - 1, (n - 1)rc)$$

$$F_B = \frac{MSB}{SSE} \sim F(c - 1, (n - 1)rc)$$

$$F_{AB} = \frac{MSAB}{SSE} \sim F((r - 1)(c - 1))$$

R codes:

Kidney

```
> kidney.lm <- lm(Days ~ Duration * weight)
> summary(kidney.lm)
```

Coefficients:

	Estimate	Std. Error	t value	Pr(> t)	
(Intercept)	2.700	1.702	1.586	0.1186	
Duration2	-0.500	2.407	-0.208	0.8362	
weight2	4.600	2.407	1.911	0.0613	.
weight3	11.900	2.407	4.943	7.84e-06	***
Duration2:weight2	-3.100	3.405	-0.911	0.3666	
Duration2:weight3	-6.600	3.405	-1.939	0.0578	.

Residual standard error: 5.383 on 54 degrees of freedom
Multiple R-squared: 0.408, Adjusted R-squared: 0.3532
F-statistic: 7.444 on 5 and 54 DF, p-value: 2.262e-05

```
> print(anova(kidney.lm))
```

Analysis of Variance Table

Response: Days

	Df	Sum Sq	Mean Sq	F value	Pr(>F)	
Duration	1	209.07	209.07	7.2147	0.009587	**
Weight	2	760.43	380.22	13.1210	2.269e-05	***
Duration:Weight	2	109.03	54.52	1.8813	0.162240	
Residuals	54	1564.80	28.98			

```
> # Another way to look at interactions
```

```
> anova(lm(Days ~ Duration + weight), kidney.lm)
```

Analysis of Variance Table

Model 1: Days ~ Duration + weight

Model 2: Days ~ Duration * weight

	Res.Df	RSS	Df	Sum of Sq	F	Pr(>F)
1	56	1673.8				
2	54	1564.8	2	109.03	1.8813	0.1622

The Kruskal-Wallis Test

a nonparametric alternative to the
one-way ANOVA

Example:

Ophthalmology

- A study was conducted to compare the anti-inflammatory effects of four different drugs in albino rabbits after administration of arachidonic acid .
- For each animal in a group, one of the four drugs was administered to one eye and a saline solution was administered to the other eye.
- Ten minutes later arachidonic acid was administered to both eyes. Both eyes were evaluated every 15 minutes thereafter for lid closure.
- assessment—a lid-closure score: 0 = eye completely open, 3 = eye completely closed, and 1, 2 = intermediate states.

Outcomes:

Ophthalmology

The measure of effectiveness (x) is the change in lid-closure score (from baseline to follow-up) in the treated eye minus the change in lid-closure score in the saline eye.

Ocular anti-inflammatory effects of four drugs on lid closure after administration of arachidonic acid

Rabbit Number	Indomethacin		Aspirin		Piroxicam		BW755C	
	Score ^a	Rank	Score	Rank	Score	Rank	Score	Rank
1	+ 2	13.5	+ 1	9.0	+ 3	20.0	+ 1	9.0
2	+ 3	20.0	+ 3	20.0	+ 1	9.0	0	4.0
3	+ 3	20.0	+ 1	9.0	+ 2	13.5	0	4.0
4	+ 3	20.0	+ 2	13.5	+ 1	9.0	0	4.0
5	+ 3	20.0	+ 2	13.5	+ 3	20.0	0	4.0
6	0	4.0	+ 3	20.0	+ 3	20.0	- 1	1.0

^a(Lid-closure score at baseline – lid-closure score at 15 minutes)_{drug eye} – (lid-closure score at baseline – lid-closure score at 15 minutes)_{saline eye}

The Kruskal-Wallis test

- In the last example, the score is ordinal variable => a nonparametric method
- generalize the Wilcoxon rank-sum test to enable us to compare more than two samples.
- Based on **ranks**
 - If the average ranks are close to each other, then H_0 , that the treatments are equally effective, is accepted.
 - If the average ranks are far apart, then H_0 is rejected and we conclude at least some of the treatments are different.

The Kruskal-Wallis test statistic

- If there are no ties,

$$H = H^* = \frac{12}{N(N+1)} \sum_{i=1}^k n_i (\bar{R}_i - \bar{\bar{R}})^2$$

- If there are ties,

$$H = \frac{H^*}{1 - \frac{1}{N^3 - N} \sum_{j=1}^g (t_j^3 - t_j)}$$

- $N = \sum_i n_i$ and R_i : the rank sum for the i th group.
- t_j : the number of observations (i.e., the frequency) with the same value in the j th cluster of tied observations
- g is the number of tied groups.

Contd.

- Applicable only if $\min(n_i) \geq 5$. (Otherwise, either the sample should be combined with another sample or special small-sample tables should be used.)
- For a level α test,
 - If $H > \chi_{\alpha, k-1}^2$, then reject H_0
 - If $H \leq \chi_{\alpha, k-1}^2$, then accept H_0
- To assess statistical significance, the p -value is approximate by

$$p = \Pr(\chi_{k-1}^2 > H)$$

Dunn Procedure

- Multiple comparison under the Kruskal-Wallis test
- To compare the i th and j th treatment groups

$$z = \frac{\bar{R}_i - \bar{R}_j}{\sqrt{\frac{N(N+1)}{12} \times \left(\frac{1}{n_i} + \frac{1}{n_j} \right)}}$$

- For a two-sided level α test, denote $\alpha^* = \frac{\alpha}{k(k-1)}$
 - If $|z| \leq z_{\alpha^*}$, then accept H_0
 - If $|z| > z_{\alpha^*}$, then reject H_0

Back to: Ophthalmology

```
> kruskal.test(ocular,g) # Kruskal-wallis rank sum  
test
```

Kruskal-wallis rank sum test

data: ocular and g


Kruskal-wallis chi-squared = 11.8041, df = 3, p-
value = 0.008085

```
> boxplot(ocular ~ g)  
> library("pgirmess")  
> kruskalmc(ocular,g)
```

Multiple comparison test after Kruskal-wallis
p.value: 0.05

Comparisons

	obs.dif	critical.dif	difference
1-2	2.083333	10.77064	FALSE
1-3	1.000000	10.77064	FA
1-4	11.916667	10.77064	TR
2-3	1.083333	10.77064	FA
2-4	9.833333	10.77064	FA
3-4	10.916667	10.77064	TR



Box-plot by groups